Skip to main content

Table 3 The reason for discontinuation of the tumour necrosis factor alpha inhibitors and the duration until discontinuation of the two groups that were included in the drug survival analysis

From: A cluster analysis of patients with axial spondyloarthritis using tumour necrosis factor alpha inhibitors based on clinical characteristics

   All patients (n = 921) Axial group (n = 737) Extra-axial group (n = 184) p-value
Inefficacy n (%) 122 (13.2) 87 (11.8) 35 (19.0) 0.014
Duration (years) 1.22 (1.20) 1.30 (1.28) 1.01 (0.97) 0.181
Adverse events n (%) 95 (10.3) 72 (9.8) 23 (12.5) 0.337
Duration (years) 0.89 (0.92) 0.97 (0.98) 0.61 (0.67) 0.049